Last Updated2026-06-02

Market View

₹131.42(▲4.41%)

Reporting PeriodQ4 FY26

IOLCPIOLCP Forensic Risk Analysis

Name: IOLCP Structural Risk Analysis
Creator: Flagium AI
License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Pharmaceuticals

Risk ClassStable

Market CapN/A

Primary DriverGovernance

Flagium AI Risk Score

10 / 100

-5 QoQ

Improving

Sentinel Insight

Financial profile remains stable for now. Pressure is receding in governance. This indicates that forensic pressure is currently receding. Risk levels are improving.

25.3th %ile (Sector)Accel: +0 Qtrs

Updated2026-06-02

Market View

₹131.42▲4.41%

PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Stability Adjustment

+10.0 pts

Final Composite Risk10 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 4 → 10 over 13 quarters.

Expected Direction

🟢 Improving

Primary Deterioration Drivers

Inventory Stress
Industrial Margin Stress
Relative Growth Weakness

What to Watch Next Quarter

Inventory turnover
Operating profit margins
Operating cash flow

Active Risk Objects (7)

CriticalHigh

Inventory Stress

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight15/15

MomentumDecaying

Last SignalQ2 FY2025

Inventory growth (18.8%) significantly outpaced revenue growth (-3.7%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Profit Collapse

📊 Earnings QualityQuarterlyActive for 1 Qtrs

More Detail

Impact Weight8/15

MomentumDecaying

Last SignalQ4 FY2024

IOLCP: Net Profit collapsed by 57.4% from FY2023 Q4 to FY2024 Q4.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Cash Conversion Deficit

📊 Earnings QualityAnnualActive for 1 Years

More Detail

Impact Weight6/15

MomentumDecaying

Last SignalFY2024

IOLCP: OCF below Net Profit in 2/3 recent years.

"Cash conversion has normalized in the latest period. Operational cash flow is back in sync."

Industrial Margin Stress

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight12/15

MomentumAccelerating

Last SignalQ3 FY2026

IOLCP: EBITDA margin compressed by 1.8 bps YoY.

"Early signs of margin erosion. Input costs are beginning to eat into core profits."

Relative Growth Weakness

📊 Earnings QualityAnnualActive for 3 Years

More Detail

Impact Weight12/15

MomentumPersistent

Last SignalQ3 FY2026

Revenue growth consistently lags behind sector median (12.8%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Capex Efficiency Stress

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight8/15

MomentumDecaying

Last SignalQ2 FY2025

Aggressive Capex (23.6%) amidst slow revenue growth (-3.7%).

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Revenue-Debt Divergence

🏛️ Solvency & LeverageAnnualActive for 1 Years

More Detail

Impact Weight6/15

MomentumDecaying

Last SignalFY2025

IOLCP: Revenue fell 2.8% while Debt rose 257.3% in 2025 vs 2024.

"Debt servicing metrics have improved recently. The company is actively deleveraging."

Risk Trajectory

Loading Chart

Resilience Matrix

Metric	Value	vs Sector	Signal
Volatility (σ)	7	7.70	✅ RESILIENT
Sensitivity (ε_s)	1	1.00	✅ RESILIENT
Escalation Prob.	5%	5%	✅ NEUTRAL
Safety Buffer	+56.0	+47.0	✅ RESILIENT

Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart

Share Price

Risk Score (0-100)

Market Performance

₹131.42(+4.41%)

1M Divergence+37.07%

1 Week-3.41%

1 Month+39.33%

6 Months+53.37%

1 Year+48.43%

2 Year+87.26%

3 Year+52.81%

Sector Average (1M)+2.27%

Sentinel Forensic Assessment

ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in governance remain well-maintained against forensic benchmarks. Systematic scans of structural transparency and audit trails confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.

IOLCP • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.92%

Trend QualityDeveloping

Phase Progression

Phase Progression Score85%

Readiness LabelHigh (Phase Transition Imminent)

Probability of Advancing92%

CoinTree Momentum

Composite Z-Score+2.4406σ

Strong positive momentum leadership

Universe Rank#70 of 2716

Top 2.58% in momentum strength

Timeframe Sparklines

1W-3.4%

1M+39.3%

6M+53.4%

Weinstein Indicators

150 DMA₹85.48

200 DMA₹89.37

150 DMA Slope+2.0270%Rising

Relative Strength+58.86%Leading

Relative Turnover (RTR)1.9875

ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).

Ticker	Risk Score	Sector %ile	Delta	Flags	Accel	Primary Driver
IOLCPIOLCP	10	25th	-5	7	+0	GovernanceStable
AARTIDRUGSAarti Drugs Limited	19	51th	-5	11	+0	Competitive PositionStable
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	23	63th	-5	20	+0	Balance Sheet StressWatch
AARTIPHARMAarti Pharmalabs Limited	35	81th	0	18	+0	Earnings QualityWatch